A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance)

EBioMedicine

Volumn 2, Issue 11, 2015, Pages 1814-1820

  Kim, Hyung L ^a   Halabi, Susan ^b   Li, Ping ^a   Mayhew, Greg ^c   Simko, Jeff ^d   Nixon, Andrew B ^c   Small, Eric J ^d   Rini, Brian ^e   Morris, Michael J ^f   Taplin, Mary Ellen ^g   George, Daniel ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GeneCentric Diagnostics   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e TAUSSIG CANCER INSTITUTE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Expression profile; Prognostic markers; Prognostic signature; Renal cell carcinoma

Indexed keywords

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; RNA EXTRACTION; CANADA; GENE EXPRESSION PROFILING; GENETICS; KAPLAN MEIER METHOD; KIDNEY TUMOR; METASTASIS; MOLECULAR MODEL; MORTALITY; PATHOLOGY; STATISTICAL MODEL; UNITED STATES;

TUMOR MARKER;

AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; CANADA; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MODELS, MOLECULAR; MODELS, STATISTICAL; NEOPLASM METASTASIS; PROGNOSIS; RISK FACTORS; UNITED STATES;

EID: 84958910533     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.09.012     Document Type: Article

References (32)

1. Brannon A.R., Reddy A., Seil er M., Arreola A., Moore D.T., Pruthi R.S., et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010, 1(2):152-163.
2. Campbell S.C., Novick A.C., Belldegrun A., Blute M.L., Chow G.K., Derweesh I.H., et al. Guideline for management of the clinical T1 renal mass. J. Urol. 2009, 182(4):1271-1279.
3. Cancer Genome Atlas Research N Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499(7456):43-49.
4. Gene [Internet]. National Center for Biotechnology Information [cited April 3, 2015] Available from:. http://www.ncbi.nlm.nih.gov/gene.
5. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366(10):883-892.
6. Gerlinger M., Catto J.W., Orntoft T.F., Real F.X., Zwarthoff E.C., Swanton C. Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications. Eur. Urol. 2014.
7. Glenn S.T., Jones C.A., Liang P., Kaushik D., Gross K.W., Kim H.L. Expression profiling of archival renal tumors by quantitative PCR to validate prognostic markers. Biotechniques 2007, 43(5). (639-40, 42-3, 47).
8. Glenn S.T., Head K.L., Teh B.T., Gross K.W., Kim H.L. Maximizing RNA yield from archival renal tumors and optimizing gene expression analysis. J. Biomol. Screen. 2010, 15(1):80-85.
9. Harshman L.C., Choueiri T.K. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J. 2013, 19(4):316-323.
10. Horie S., Aruga S., Kawamata H., Okui N., Kakizoe T., Kitamura T. Biological role of HGF/MET pathway in renal cell carcinoma. J. Urol. 1999, 161(3):990-997.
11. Jones J., Otu H., Spentzos D., Kolia S., Inan M., Beecken W.D., et al. Gene signatures of progression and metastasis in renal cell cancer. Clin. Cancer Res. 2005, 11(16):5730-5739.
12. Kim H.L., Seligson D., Liu X., Janzen N., Bui M.H., Yu H., et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J. Urol. 2005, 173(5):1496-1501.
13. Koochekpour S., Jeffers M., Wang P.H., Gong C., Taylor G.A., Roessler L.M., et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol. Cell. Biol. 1999, 19(9):5902-5912.
14. Kosari F., Parker A.S., Kube D.M., Lohse C.M., Leibovich B.C., Blute M.L., et al. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin. Cancer Res. 2005, 11(14):5128-5139.
15. Kusuda Y., Miyake H., Behnsawy H.M., Fukuhara T., Inoue T.A., Fujisawa M. Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens. Urol. Oncol. 2013, 31(1):42-50.
16. Li P., Grigorenko E., Funari V., Enright E., Zhang H., Kim H.L. Evaluation of a high-throughput, microfluidics platform for performing TaqMan qPCR using formalin-fixed paraffin-embedded tumors. Bioanalysis 2013, 5(13):1623-1633.
17. Lin C.Y., Halabi S. A simple method for deriving the confidence regions for the penalized Cox's model via the minimand perturbation. Communications in Statistics: Theorey and Methods 2015, (in press).
18. Minnier J., Tian L., Cai T. A Perturbation Method for Inference on Regularized Regression Estimates. J. Am. Stat. Assoc. 2011, 106(496):1371-1382.
19. Miyake H., Sakai I., Muramaki M., Kurahashi T., Takenaka A., Fujisawa M. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens. Int. J. Urol. 2009, 16(5):465-471.
20. Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002, 20(1):289-296.
21. Nogueira M., Kim H.L. Molecular markers for predicting prognosis of renal cell carcinoma. Urol. Oncol. 2008, 26(2):113-124.
22. Rini B.I., Halabi S., Rosenberg J.E., Stadler W.M., Vaena D.A., Ou S.S., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 2008, 26(33):5422-5428.
23. Rini B.I., Halabi S., Rosenberg J.E., Stadler W.M., Vaena D.A., Archer L., et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 2010, 28(13):2137-2143.
24. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3(6):1101-1108.
25. Sultmann H., von Heydebreck A., Huber W., Kuner R., Buness A., Vogt M., et al. Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin. Cancer Res. 2005, 11(2 Pt 1):646-655.
26. Takahashi M., Rhodes D.R., Furge K.A., Kanayama H., Kagawa S., Haab B.B., et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(17):9754-9759.
27. Tibshirani R. The lasso method for variable selection in the Cox model. Stat. Med. 1997, 16(4):385-395.
28. Tsavachidou-Fenner D., Tannir N., Tamboli P., Liu W., Petillo D., Teh B., et al. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann. Oncol. 2010, 21(8):1599-1606.
29. Tun H.W., Marlow L.A., von Roemeling C.A., Cooper S.J., Kreinest P., Wu K., et al. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One 2010, 5(5).
30. Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469(7331):539-542.
31. Vasselli J.R., Shih J.H., Iyengar S.R., Maranchie J., Riss J., Worrell R., et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(12):6958-6963.
32. Zhao H., Ljungberg B., Grankvist K., Rasmuson T., Tibshirani R., Brooks J.D. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med. 2006, 3(1).